Krystal Biotech Q2 revenue rises on VYJUVEK strength

Krystal Biotech

03/08/2026 12:12

Overview
US genetic medicines developer's Q2 product revenue grew 24% yr/yr to $119.2 mln
Adjusted EPS for Q2 rose to $1.79 from $1.29 a year ago
Company ended Q2 with $1.1 bln in cash and investments

Outlook
Krystal Biotech expects VYJUVEK launches in Spain and Italy before year end
Company expects multiple clinical data readouts in 2H 2026
Company sees FY 2026 non-GAAP R&D and SG&A expense at $175 mln to $195 mln

Result Drivers
VYJUVEK DEMAND - Co said Q2 revenue growth was driven by durable demand for VYJUVEK in the US and internationally, with expanding prescriber base and broad reimbursement access
PATIENT SUPPORT INITIATIVES - Co said patient support programs and a recent label update helped DEB patients integrate VYJUVEK into ongoing wound care routines

Company press release: ID:nGNX7Klr70

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$119.22 mln
 
Q2 EPS
 
$1.79
 
Q2 Net Income
 
$54.77 mln
 
Q2 Operating Expenses
 
$60.81 mln
 
Q2 Operating Income
 
$58.42 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Krystal Biotech Inc is $386.50, about 13.3% above its July 31 closing price of $341.12
The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 31 three months ago

Reuters Recommended Reads
July 31 - Moderna posts smaller-than-expected Q2  loss per share on lower R&D spending 
July 31 - AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates
Aug 2 - For GLP-1 users, the in-store clothes shopping trip is back

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)